Recent News

April 1, 2025

Sydnexis Announces Positive CHMP Opinion in Europe for SYD-101 for Slowing the Progression of Pediatric Myopia

View Source

Santen is Sydnexis’ Licensing Partner to Commercialize SYD-101 within the EMEA Region upon issuance of a Marketing Authorization by the European Commission

DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc. (www.sydnexis.com), a pre-commercial stage biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for its proprietary low-dose atropine formulation, SYD-101, for slowing the progression of pediatric myopia. Santen SA licensed the rights from Sydnexis to commercialize SYD-101 under the brand name Ryjunea® in the regions of Europe, Middle East, and Africa (EMEA). Santen SA is the Switzerland-based affiliate of Santen Pharmaceutical Co., Ltd., a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide.

“This is an incredible milestone for Sydnexis and comes on the heels of the FDA accepting our NDA for SYD-101 and assigning a PDUFA date of October 23, 2025,” said Perry Sternberg, Chief Executive Officer of Sydnexis. “The CHMP positive opinion provides further validation of both the significant unmet need and critical importance of early intervention and endorses the potential benefit SYD-101 can provide to millions of pediatric patients with progressive myopia.”

The CHMP positive opinion was primarily supported by data from the STAR study, Sydnexis’ pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities. Santen reported Ryjunea® met its EMA primary endpoint demonstrating efficacy in slowing the annual progression rate of myopia in pediatric patients ages 3 to 14 years-old at 24 months.

“Santen recognized early on that SYD-101’s novel, proprietary formulation was unique in its ability to deliver superior drug activity, maximum stability, and optimal comfort,” said Patrick Johnson, Ph.D., President of Sydnexis. “They have been a great partner, and we are excited for Santen to bring SYD-101 to market across multiple continents.”

Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life.

“I am thrilled about the progress to bring SYD-101 to market for the millions of pediatric patients impacted by this growing epidemic,” said Professor Mark Bullimore, OD, Ph.D. “The news of CHMP’s positive opinion should have a huge impact in Europe, where low-dose atropine has been largely unavailable.”

About Sydnexis, Inc.:

Founded in 2014, Sydnexis, Inc. (www.sydnexis.com) is a privately held, pre-commercial stage

biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-
year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose

atropine formulation to slow progression of pediatric myopia and the risk of associated co-
morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for

exploratory endpoints and third year results will be announced upon completion of the fourth year
of the study. The company is venture-backed by four major investors: RA Capital, Longitude
Capital, Visionary Ventures, and Bluestem Capital.
For media inquiries, please contact: media@launchlabpartners.com

Sydnexis may use and disclose online usage data about you collected automatically through online tracking technologies such as cookies, pixels, and web beacons (collectively, "cookies"). We use this data for multiple purposes, including for online targeted advertising (advertisements based on your interests inferred from your activity across other unaffiliated sites and services) and website analytics purposes, as well as to personalize content, save your preferences, provide social media features, and track the site’s performance, as further described in the "Cookies and similar tracking and data collection technologies" section of our Privacy Notice. We retain this data for as long as necessary to fulfill these purposes or as needed to comply with our record retention obligations. We do not sell your data, but we may disclose it to our marketing and advertising partners for purposes of online targeted advertising or for website analytics purposes. To opt out of the use or disclosure of your cookie-based personal data for online targeted advertising or for website analytics purposes, or to otherwise manage your preferences, please click on Cookie Settings below. For additional information on the categories of data we collect, the purposes for their collection, disclosures to third parties, and data retention, please visit our Privacy Notice.